Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HPP

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

National Institute for Health and Care Excellence NICE logo

NICE forced to look again at Alimta

Procedural error forces watchdog to reconsider rejection of Lilly's lung cancer

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links